

## 包括的腫瘍学分野

### 論文

#### A 欧文

A-a

- 1 . Noguchi R, Yoshimatsu Y, Sin Y, Ono T, Tsuchiya R, Yoshida H, Kiyono T, Yonemura Y, Kondo T.: Establishment and characterization of NCC-PMP2-C1: a novel patient-derived cell line of pseudomyxoma peritonei with signet ring cells. *Human Cell* 37(2): 511-522,2023. doi: 10.1007/s13577-023-01015-0. (IF: 4.374)
- 2 . Yoshimatsu Y, Noguchi R, Osaki J, Sin Y, Tsuchiya R, Ono T, Akiyama T, Adachi Y, Tanzawa Y, Yoshida A, Kawai A, Kondo T: Establishment and characterization of NCC-LMS3-C1: a novel patient-derived cell line of leiomyosarcoma. *Human Cell* 37(1): 337-344,2023. doi: 10.1007/s13577-023-00991-7. (IF: 4.374)
- 3 . Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Ogura K, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. : Establishment and characterization of NCC-DFSP4-C1: a novel cell line from a patient with dermatofibrosarcoma protuberans having the fibrosarcomatous transformation.. *Human Cell* 36(6): 2187-2194,2023. doi: 10.1007/s13577-023-00932-4. (IF: 4.374)
- 4 . Ono T, Noguchi R, Yoshimatsu Y, Sin Y, Tsuchiya R, Akiyama T, Kojima N, Toda Y, Sato C, Fukushima S, Yoshida A, Kawai A, Kondo T. : Establishment and characterization of two novel patient-derived cell lines from giant cell tumor of bone. *Human Cell* 36(5): 1804-1812,2023. doi: 10.1007/s13577-023-00928-0. (IF: 4.374)
- 5 . Tsuchiya R, Yoshimatsu Y, Noguchi R, Sin Y, Ono T, Akiyama T, Kosako H, Yoshida A, Ohtori S, Kawai A, Kondo T: Integrating analysis of proteome profile and drug screening identifies therapeutic potential of MET pathway for the treatment of malignant peripheral nerve sheath tumor.. *Expert Rev Proteomics* 20(4): 109-119,2023. doi: 10.1080/14789450.2023.2218035. (IF: 4.374)
- 6 . Ono T, Kondo T: Data of distinct stromal protein expressions between sarcoma patient-derived models and their primary tumors. *Journal of Proteome Data and Methods* 5: 11-12,2023. doi: <https://doi.org/10.14889/jpdm.2023.0011>. (IF: 4.374)
- 7 . Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Ono T, Adachi Y, Tsuchiya R, Toda Y, Kobayashi E, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T. : stablishment and characterization of NCC-DSM1-C1: a novel cell line derived from a patient with desmoid fibromatosis. *Human Cell* 36(2): 847-853,2023. doi: 10.1007/s13577-022-00850-x. (IF: 4.374)
- 8 . Akiyama T, Yoshimatsu Y, Noguchi R, Sin Y, Osaki J, Adachi Y, Ono T, Tsuchiya R, Sato C, Iwata S, Kojima N, Yoshida A, Ohtori S, Kawai A, Kondo T: Establishment and characterization of NCC-PLPS2-C1: a novel cell line of pleomorphic liposarcoma. *Human Cell* 36(1): 468-475,2023. doi: 10.1007/s13577-022-00828-9. (IF: 4.374)
- 9 . Kunimasa K, Matsumoto S, Honma K, Tamiya M, Inoue T, Kawamura T, Tanada S, Miyazaki A, Kanzaki R, Maniwa T, Okami J, Matsumoto Y, Goto K, Nishino K: Utility of needle biopsy in centrally located lung cancer for genome analysis: a retrospective cohort study. *BMC Pulm Med* 23(1): 484,2023. doi: 10.1186/s12890-023-02749-1. (IF: 2.6)
- 10 . Goto K, Goto Y, Kubo T, Ninomiya K, Kim SW, Planchard D, Ahn MJ, Smit EF, de Langen AJ, Pérol M, Pons-Tostivint E, Novello S, Hayashi H, Shimizu J, Kim DW, Kuo CH, Yang JC, Pereira K, Cheng FC, Taguchi A, Cheng Y, Feng W, Tsuchihashi Z, Jänne PA: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. *J Clin Oncol* 41(31): 4852-4863,2023. doi: 10.1200/jco.23.01361. (IF: 42.1)
- 11 . Sakai T, Matsumoto S, Ueda Y, Shibata Y, Ikeda T, Nakamura A, Kodani M, Ohashi K, Furuya N, Izumi H, Nosaki K, Umemura S, Zenke Y, Udagawa H, Sugiyama E, Yoh K, Goto K: Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia). *J Thorac Oncol* 18(11): 1538-1549,2023. doi: 10.1016/j.jtho.2023.07.024. (IF: 21)
- 12 . Shiraishi T, Yamasaki K, Kidogawa M, Shingu T, Ujimiya F, Jotatsu T, Matsumoto S, Izumi H, Nishida C, Goto K, Yatera K: Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene. *Intern Med* 62(21): 3215-3221,2023. doi: 10.2169/internalmedicine.1164-22. (IF: 1)

- 13 . Wolf J, Souquet PJ, Goto K, Cortot A, Baik C, Heist R, Kim TM, Han JY, Neal JW, Mansfield AS, Gilloteau I, Nwana N, Waldron-Lynch M, Davis KL, Giovannini M, Awad MM: Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review. *Clin Lung Cancer* 24(7): 641-650,2023. doi: 10.1016/j.clcc.2023.08.011. (IF: 3.3)
- 14 . Zhou C, Solomon B, Loong HH, Park K, Pérol M, Arriola E, Novello S, Han B, Zhou J, Ardizzoni A, Mak MP, Santini FC, Elamin YY, Drilon A, Wolf J, Payakachat N, Uh MK, Rajakumar D, Han H, Puri T, Soldatenkova V, Lin AB, Lin BK, Goto K: First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. *N Engl J Med* 389(20): 1839-1850,2023. doi: 10.1056/NEJMoa2309457. (IF: 96.2)
- 15 . Oyoshi H, Hirata H, Hirano Y, Zenda S, Zhou Y, Tomizawa K, Fujisawa T, Nakamura M, Hojo H, Motegi A, Kageyama SI, Zenke Y, Goto K, Ishihara S, Naganawa S, Akimoto T: Prognostic impact of EGFR/ALK alterations in leptomeningeal metastasis from lung adenocarcinoma treated with whole-brain radiotherapy. *Clin Exp Metastasis* 40(5): 407-413,2023. doi: 10.1007/s10585-023-10225-7. (IF: 5.15)
- 16 . Tanaka T, Umemura S, Miyoshi T, Nakai T, Noritake O, Suzuki J, Tane K, Samejima J, Aokage K, Mimaki S, Tsuchihara K, Taki T, Miyazaki S, Watanabe R, Sakashita S, Sakamoto N, Kojima M, Goto K, Ikeda N, Tsuboi M, Ishii G: The prognostic impact of a high number of peritumoral alveolar macrophages in neuroendocrine carcinoma in the lung. *Pathol Int* 73(10): 497-508,2023. doi: 10.1111/pin.13365. (IF: 2.5)
- 17 . Ohtani-Kim SJ, Taki T, Tane K, Miyoshi T, Samejima J, Aokage K, Nagasaki Y, Kojima M, Sakashita S, Watanabe R, Sakamoto N, Goto K, Tsuboi M, Ishii G: Efficacy of Preoperative Biopsy in Predicting the Newly Proposed Histologic Grade of Resected Lung Adenocarcinoma. *Mod Pathol* 36(9): 100209,2023. doi: 10.1016/j.modpat.2023.100209. (IF: 7.1)
- 18 . Yoshida T, Kumagai T, Toyozawa R, Katayama R, Nishio M, Seto T, Goto K, Yamamoto N, Ohe Y, Kudou K, Asato T, Zhang P, Nakagawa K: Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. *Cancer Sci* 114(9): 3698-3707,2023. doi: 10.1111/cas.15888. (IF: 4.5)
- 19 . Kagawa Y, Nakai T, Taki T, Hashimoto H, Tanaka Y, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Watanabe R, Kojima M, Sakashita S, Sakamoto N, Tsuboi M, Goto K, Ishii G: Prognostic impact and gene expression analysis of peri-tumoral alveolar macrophage in resected lung adenocarcinoma. *Cancer Sci* 114(8): 3423-3432,2023. doi: 10.1111/cas.15848. (IF: 4.5)
- 20 . Shimokawa T, Okamoto H, Machida R, Misumi Y, Hosomi Y, Yoneshima Y, Tanaka H, Okishio K, Simizu J, Goto K, Akamatsu H, Kubota K, Nakagawa K, Horinouchi H, Ando M, Kataoka T, Ohe Y: Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial. *Lung Cancer* 181: 107195,2023. doi: 10.1016/j.lungcan.2023.107195. (IF: 5.71)
- 21 . Tanaka Y, Nakai T, Suzuki A, Kagawa Y, Noritake O, Taki T, Hashimoto H, Sakai T, Shibata Y, Izumi H, Nosaki K, Udagawa H, Zenke Y, Matsumoto S, Yoh K, Miyazaki S, Sakamoto N, Sakashita S, Kojima M, Watanabe R, Tsuboi M, Goto K, Ishii G: Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma. *Cancer Immunol Immunother* 72(7): 2205-2215,2023. doi: 10.1007/s00262-023-03393-8. (IF: 4.6)
- 22 . Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T, Nakagawa K, Yoshioka H, Nogami N, Maemondo M, Nagase S, Okamoto I, Yamamoto N, Igawa Y, Tajima K, Fukuoka M, Yamamoto N, Nishio K: Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+ non-small-cell lung cancer. *Transl Lung Cancer Res* 12(6): 1167-1184,2023. doi: 10.21037/tlcr-22-632. (IF: 4)
- 23 . Kunimasa K, Matsumoto S, Kawamura T, Inoue T, Tamiya M, Kanzaki R, Maniwa T, Okami J, Honma K, Goto K, Nishino K: Clinical application of the AMOY 9-in-1 panel to lung cancer patients. *Lung Cancer* 179: 107190,2023. doi: 10.1016/j.lungcan.2023.107190. (IF: 4.5)

- 24 . Shi J, Shiraishi K, Choi J, Matsuo K, Chen TY, Dai J, Hung RJ, Chen K, Shu XO, Kim YT, Landi MT, Lin D, Zheng W, Yin Z, Zhou B, Song B, Wang J, Seow WJ, Song L, Chang IS, Hu W, Chien LH, Cai Q, Hong YC, Kim HN, Wu YL, Wong MP, Richardson BD, Funderburk KM, Li S, Zhang T, Breeze C, Wang Z, Blechter B, Bassig BA, Kim JH, Albanes D, Wong JYY, Shin MH, Chung LP, Yang Y, An SJ, Zheng H, Yatabe Y, Zhang XC, Kim YC, Caporaso NE, Chang J, Ho JCM, Kubo M, Daigo Y, Song M, Momozawa Y, Kamatani Y, Kobayashi M, Okubo K, Honda T, Hosgood DH, Kunitoh H, Patel H, Watanabe SI, Miyagi Y, Nakayama H, Matsumoto S, Horinouchi H, Tsuboi M, Hamamoto R, Goto K, Ohe Y, Takahashi A, Goto A, Minamiya Y, Hara M, Nishida Y, Takeuchi K, Wakai K, Matsuda K, Murakami Y, Shimizu K, Suzuki H, Saito M, Ohtaki Y, Tanaka K, Wu T, Wei F, Dai H, Machiela MJ, Su J, Kim YH, Oh IJ, Lee VHF, Chang GC, Tsai YH, Chen KY, Huang MS, Su WC, Chen YM, Seow A, Park JY, Kweon SS, Chen KC, Gao YT, Qian B, Wu C, Lu D, Liu J, Schwartz AG, Houlston R, Spitz MR, Gorlov IP, Wu X, Yang P, Lam S, Tardon A, Chen C, Bojesen SE, Johansson M, Risch A, Bickeböller H, Ji BT, Wichmann HE, Christiani DC, Rennert G, Arnold S, Brennan P, McKay J, Field JK, Shete SS, Le Marchand L, Liu G, Andrew A, Kiemeny LA, Zienolddiny-Narui S, Grankvist K, Johansson M, Cox A, Taylor F, Yuan JM, Lazarus P, Schabath MB, Aldrich MC, Jeon HS, Jiang SS, Sung JS, Chen CH, Hsiao CF, Jung YJ, Guo H, Hu Z, Burdett L, Yeager M, Hutchinson A, Hicks B, Liu J, Zhu B, Berndt SI, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Wang WC, Xu J, Guan P, Tan W, Yu CJ, Yang G, Sihoe ADL, Chen Y, Choi YY, Kim JS, Yoon HI, Park IK, Xu P, He Q, Wang CL, Hung HH, Vermeulen RCH, Cheng I, Wu J, Lim WY, Tsai FY, Chan JKC, Li J, Chen H, Lin HC, Jin L, Liu J, Sawada N, Yamaji T, Wyatt K, Li SA, Ma H, Zhu M, Wang Z, Cheng S, Li X, Ren Y, Chao A, Iwasaki M, Zhu J, Jiang G, Fei K, Wu G, Chen CY, Chen CJ, Yang PC, Yu J, Stevens VL, Fraumeni JF, Jr., Chatterjee N, Gorlova OY, Hsiung CA, Amos CI, Shen H, Chanock SJ, Rothman N, Kohno T, Lan Q: Genome-wide association study of lung adenocarcinoma in East Asia and comparison with a European population. *Nat Commun* 14(1): 3043,2023. doi: 10.1038/s41467-023-38196-z. (IF: 14.7)
- 25 . Yu Y, Zhou J, Li X, Goto K, Min X, Nishino K, Cui J, Wu L, Sakakibara J, Shu Y, Dong X, Li L, Yoneshima Y, Zhou C, Li X, Zhang Y, Huang D, Zang A, Zhang W, Wang X, Zhang L, Bai C, Fang J, Cao L, Zhao Y, Yu Y, Shi M, Zhong D, Li F, Li M, Wu Q, Zhou J, Sun M, Lu S: Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial. *EClinicalMedicine* 59: 101952,2023. doi: 10.1016/j.eclinm.2023.101952. (IF: 3.59)
- 26 . Sugimoto A, Matsumoto S, Udagawa H, Itotani R, Usui Y, Umemura S, Nishino K, Nakachi I, Kuyama S, Daga H, Hara S, Miyamoto S, Kato T, Sakakibara-Konishi J, Tabata E, Nakagawa T, Kawaguchi T, Sakai T, Shibata Y, Izumi H, Nosaki K, Zenke Y, Yoh K, Goto K: A large-scale prospective concordance study of plasma- and tissue-based next-generation targeted sequencing for advanced non-small cell lung cancer (LC-SCRUM-Liquid). *Clin Cancer Res* 29(8): 1506-1514,2023. doi: 10.1158/1078-0432.Ccr-22-1749. (IF: 10)
- 27 . Goto K, Shiraishi Y, Murakami H, Horinouchi H, Toyozawa R, Takeda M, Uno M, Crawford N, McGill J, Jimbo T, Ishigami M, Takayama G, Nakayama S, Ohwada S, Nishio M: Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer. *Cancer Med* 12(6): 7090-7104,2023. doi: 10.1002/cam4.5508. (IF: 2.9)
- 28 . Kagawa Y, Hayashida T, Liu J, Mori S, Izumi H, Kumagai S, Udagawa H, Hattori N, Goto K, Kobayashi SS: The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations. *JTO Clin Res Rep* 4(3): 100462,2023. doi: 10.1016/j.jto.2023.100462.
- 29 . Noda-Narita S, Naito T, Udagawa H, Goto K, Miyawaki T, Mamesaya N, Nakashima K, Kenmotsu H, Shimokawaji T, Kato T, Hakozaiki T, Okuma Y, Nakamura M, Nakayama Y, Watanabe H, Kusumoto M, Ohe Y, Horinouchi H: Nivolumab-induced radiation recall pneumonitis in non-small cell lung cancer patients with thoracic radiation therapy. *Cancer Sci* 114(2): 630-639,2023. doi: 10.1111/cas.15621. (IF: 4.5)
- 30 . Tamiya Y, Matsumoto S, Zenke Y, Yoh K, Ikeda T, Shibata Y, Kato T, Nishino K, Nakamura A, Furuya N, Miyamoto S, Kuyama S, Nomura S, Ikeno T, Udagawa H, Sugiyama E, Nosaki K, Izumi H, Sakai T, Hashimoto N, Goto K: Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study. *Lung Cancer* 176: 103-111,2023. doi: 10.1016/j.lungcan.2022.12.019. (IF: 4.5)
- 31 . Drilon A, Subbiah V, Gautschi O, Tomasini P, de Braud F, Solomon BJ, Shao-Weng Tan D, Alonso G, Wolf J, Park K, Goto K, Soldatenkova V, Szymczak S, Barker SS, Puri T, Bence Lin A, Loong H, Besse B: Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. *J Clin Oncol* 41(2): 385-394,2023. doi: 10.1200/jco.22.00393. (IF: 44.54)
- 32 . Sakai T, Aokage K, Miyoshi T, Tane K, Ishii G, Goto K, Tsuboi M: Tumor size exceeding 5 cm as a valid prognostic factor in all stages of thymic epithelial tumors. *Surg Today* 53(1): 42-50,2023. doi: 10.1007/s00595-022-02530-7. (IF: 1.7)

- 33 . Sakai T, Aokage K, Miyoshi T, Tane K, Ishii G, Goto K, Tsuboi M: Correction to: Tumor size exceeding 5 cm as a valid prognostic factor in all stages of thymic epithelial tumors. *Surg Today* 53(1): 51,2023. doi: 10.1007/s00595-022-02586-5. (IF: 2.55)
- 34 . Watanabe K, Gomez AM, Kuramitsu S, Siurala M, Da T, Agarwal S, Song D, Scholler J, Rotolo A, Posey AD, Rook AH, Haun PL, Ruella M, Young RM, June CH.: Identifying highly active anti-CCR4 CAR T cells for the treatment of T-cell lymphoma.. *Blood Adv* 7(14): 3416-3430,2023. doi: 10.1182/bloodadvances.2022008327.. (IF: 7.4)
- 35 . Sakuramachi M, Murakami N, Nagao A, Kojima K, Miyata Y, Kashihara T, Kaneda T, Takahashi K, Inaba K, Okuma K, Nakayama Y, Okamoto H, Ishikawa M, Igaki H.: Hydrogel spacer injection to the meso-sigmoid to protect the sigmoid colon in cervical cancer brachytherapy: A technical report. *J Contemp Brachytherapy*. 15(6): 465-469,2023. doi: 10.5114/jcb.2023.134174. (IF: 1.19)
- 36 . Wada S, Ogata D, Kashihara T, Okuma K, Eto H, Nakano E, Takahashi A, Namikawa K, Igaki H, Yamazaki N.: A single-center retrospective analysis of prognoses in patients with melanoma brain metastases and effectiveness of treatment in Japan. *Cancer Med*. 12(24): 21933-21943,2023. doi: 10.1002/cam4.6767. (IF: 4.711)
- 37 . Egashira M, Arimura H, Kobayashi K, Moriyama K, Kodama T, Tokuda T, Ninomiya K, Okamoto H, Igaki H.: Magnetic resonance-based imaging biopsy with signatures including topological Betti number features for prediction of primary brain metastatic sites. *Phys Eng Sci Med*. 46(4): 1411-1426,2023. doi: 10.1007/s13246-023-01308-6. (IF: 2.4)
- 38 . Nagao A, Okamoto H, Nakayama H, Chiba T, Fujiyama D, Kuwahara J, Sakasai T, Kashihara T, Kaneda T, Inaba K, Okuma K, Murakami N, Igaki H.: Assessment of intrafractional motion of the cervix-uterus by MR-guided radiotherapy system†. *J Radiat Res*. 64(6): 967-972,2023. doi: 10.1093/jrr/rrad072. (IF: 1.94)
- 39 . Murakami N, Kojima K, Okuma K, Kashihara T, Nakamura S, Shimizu W, Suda R, Igaki H, Shikama N.: Non-operative management involving chemoradiation therapy combined with high-dose-rate brachytherapy for T3 rectal cancer using a vaginal shielded cylindrical applicator: a technical report. *Jpn J Clin Oncol*. 53(11): 1082-1086,2023. doi: 10.1093/jjco/hyad099. (IF: 1.9)
- 40 . Kawauchi D, Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Omura T, Yoshida A, Kubo Y, Igaki H, Ichimura K, Narita Y.: Consulting a neurosurgeon upon initial medical assessment reduces the time to the first surgery and potentially contributes to improved prognosis for glioblastoma patients. *Jpn J Clin Oncol*. 53(11): 1027-1033,2023. doi: 10.1093/jjco/hyad093. (IF: 1.9)
- 41 . Kashihara T, Mori T, Nakaichi T, Nakamura S, Ito K, Kurihara H, Kusumoto M, Itami J, Yoshimoto S, Igaki H.: Correlation between L-amino acid transporter 1 expression and 4-borono-2-(18) F-fluoro-phenylalanine accumulation in humans. *Cancer Med*. 12(21): 20564-20572,2023. doi: 10.1002/cam4.6635. (IF: 4.711)
- 42 . Igaki H, Nakamura S, Yamazaki N, Kaneda T, Takemori M, Kashihara T, Murakami N, Namikawa K, Nakaichi T, Okamoto H, Iijima K, Chiba T, Nakayama H, Nagao A, Sakuramachi M, Takahashi K, Inaba K, Okuma K, Nakayama Y, Shimada K, Nakagama H, Itami J.: Acral cutaneous malignant melanoma treated with linear accelerator-based boron neutron capture therapy system: a case report of first patient. *Front Oncol*. 13: 1272507,2023. doi: 10.3389/fonc.2023.1272507. (IF: 3.5)
- 43 . Eguchi K, Omura G, Murakami N, Honma Y, Yokoyama K, Watanabe T, Aihara Y, Sakai A, Matsumoto Y, Sakai T, Kobayashi K, Igaki H, Yoshimoto S.: Comparison of Survival Outcomes Between Larynx-Preserving Open Partial Pharyngectomy and Radiotherapy or Chemoradiotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis with Inverse Probability of Treatment Weighting Adjustments. *Ann Surg Oncol*. 30(11): 6867-6874,2023. doi: 10.1245/s10434-023-13934-1. (IF: 3.4)
- 44 . Kishigami Y, Nakamura M, Nakao M, Okamoto H, Takahashi A, Igaki H.: Three-dimensional assessment of interfractional cervical and uterine motions using daily magnetic resonance images to determine margins and timing of replanning. *J Appl Clin Med Phys*. 24(10): e14073,2023. doi: 10.1002/acm2.14073. (IF: 2.1)
- 45 . Adachi M, Matsumoto Y, Furuse H, Uchimura K, Imabayashi T, Yotsukura M, Yoshida Y, Nakagawa K, Igaki H, Watanabe SI, Tsuchida T.: Utility of the endobronchial Watanabe spigot for intractable cancer-related pneumothorax: a retrospective observational study. *Jpn J Clin Oncol*. 53(9): 829-836,2023. doi: 10.1093/jjco/hyad060. (IF: 1.9)
- 46 . Imamichi S, Chen L, Ito T, Tong Y, Onodera T, Sasaki Y, Nakamura S, Mauri P, Sanada Y, Igaki H, Murakami Y, Suzuki M, Itami J, Masunaga S, Masutani M.: Correction: Imamichi et al. Extracellular Release of HMGB1 as an Early Potential Biomarker for the Therapeutic Response in a Xenograft Model of Boron Neutron Capture Therapy. *Biology* 2022, 11, 420. *Biology (Basel)*. 12(8): 1112,2023. doi: 10.3390/biology12081112. (IF: 3.6)

- 47 . Imaizumi J, Shida D, Boku N, Igaki H, Itami J, Miyakita Y, Narita Y, Takashima A, Kanemitsu Y.: Prognostic factors associated with the transition in treatment methods for brain metastases from colorectal cancer. *Int J Clin Oncol.* 28(8): 1043-1053,2023. doi: 10.1007/s10147-023-02352-8. (IF: 2.4)
- 48 . Doi Y, Nagata Y, Matsumoto Y, Numata K, Sasaki R, Yamada T, Igaki H, Imagumbai T, Katoh N, Yoshitake T, Shimizuguchi T, Fujioka D, Inoue M, Koide Y, Kimura T, Ito Y.: Multicenter retrospective study of stereotactic body radiotherapy for patients with previously untreated initial small hepatocellular carcinoma. *Hepatol Res.* 53(8): 749-760,2023. doi: 10.1111/hepr.13908. (IF: 3.85)
- 49 . Eguchi K, Omura G, Shimoi T, Kageyama D, Igaki H, Abe Y, Watanabe T, Aihara Y, Sakai A, Matsumoto Y, Sakai T, Yonemori K, Mori T, Yoshida A, Yoshimoto S.: BCOR-CCNB3 sarcoma arising in the pharynx. *Auris Nasus Larynx.* 50(4): 618-622,2023. doi: 10.1016/j.anl.2022.04.012. (IF: 1.6)
- 50 . Murakami N, Nakatani F, Takahashi K, Nakamura S, Igaki H, Shikama N.: Salvage high-dose rate brachytherapy for myxofibrosarcoma of the brachium: a technical report. *J Radiat Res.* 64(4): 746-749,2023. doi: 10.1093/jrr/rrad041. (IF: 1.94)
- 51 . Nakamura S, Imamichi S, Shimada K, Takemori M, Kanai Y, Iijima K, Chiba T, Nakayama H, Nakaichi T, Mikasa S, Urago Y, Kashihara T, Takahashi K, Nishio T, Okamoto H, Itami J, Ishiai M, Suzuki M, Igaki H, Masutani M.: Relative biological effectiveness for epithermal neutron beam contaminated with fast neutrons in the linear accelerator-based boron neutron capture therapy system coupled to a solid-state lithium target. *J Radiat Res.* 64(4): 661-667,2023. doi: 10.1093/jrr/rrad037. (IF: 1.94)
- 52 . Okamoto H, Murakami N, Isohashi F, Kasamatsu T, Hasumi Y, Kobayashi H, Ishikawa M, Nakamura M, Nishio T, Igaki H, Ishikura S, Yaegashi N, Mizowaki T, Nishimura Y, Toita T.: Plan quality association between dummy run and individual case review in a prospective multi-institutional clinical trial of postoperative cervical cancer patients treated with intensity-modulated radiotherapy: Japan clinical Oncology Group study (JCOG1402). *Radiother Oncol.* 183: 109630,2023. doi: 10.1016/j.radonc.2023.109630. (IF: 4.9)
- 53 . Murakami N, Masui K, Yoshida K, Noda SE, Watanabe M, Takenaka T, Ii N, Atsumi K, Umezawa R, Inaba K, Iijima K, Kubo A, Igaki H, Shikama N, Ikushima H.: Hands-on seminar for image-guided adaptive brachytherapy and intracavitary/interstitial brachytherapy for uterine cervical cancer. *Jpn J Clin Oncol.* 53(6): 508-513,2023. doi: 10.1093/jjco/hyad012. (IF: 1.9)
- 54 . Yoshioka Y, Sasamura K, Ito M, Kaneko M, Takahashi T, Anno W, Shimoyachi N, Suzuki J, Okuda T, Kashihara T, Inaba K, Igaki H, Itami J.: Treatment planning comparison of high-dose-rate brachytherapy vs. robotic and conventional stereotactic body radiotherapy for ultrahypofractionated treatment of prostate cancer. *Phys Imaging Radiat Oncol.* 26: 100445,2023. doi: 10.1016/j.phro.2023.100445. (IF: 3.4)
- 55 . Nakayama H, Okamoto H, Nakamura S, Iijima K, Chiba T, Takemori M, Nakaichi T, Mikasa S, Fujii K, Sakasai T, Kuwahara J, Miura Y, Fujiyama D, Tsunoda Y, Hanzawa T, Igaki H, Chang W.: Film measurement and analytical approach for assessing treatment accuracy and latency in a magnetic resonance-guided radiotherapy system. *J Appl Clin Med Phys.* 24(5): e13915,2023. doi: 10.1002/acm2.13915. (IF: 2.1)
- 56 . Murakami N, Watanabe M, Uno T, Sekii S, Tsujino K, Kasamatsu T, Machitori Y, Aoshika T, Kato S, Hirowatari H, Kaneyasu Y, Nakagawa T, Ikushima H, Ando K, Murata M, Yoshida K, Yoshioka H, Murata K, Ohno T, Okonogi N, Saito AI, Ichikawa M, Okuda T, Tsuchida K, Sakurai H, Yoshimura R, Yoshioka Y, Yorozu A, Kunitake N, Okamoto H, Inaba K, Kato T, Igaki H, Itami J.: Phase I/II prospective clinical trial for the hybrid of intracavitary and interstitial brachytherapy for locally advanced uterine cervical cancer. *J Gynecol Oncol.* 34(3): e24,2023. doi: 10.3802/jgo.2023.34.e24. (IF: 2.599)
- 57 . Nakaichi T, Okamoto H, Kon M, Takaso K, Aikawa A, Nakamura S, Ijima K, Chiba T, Nakayama H, Takemori M, Mikasa S, Fujii K, Urago Y, Goka T, Shimizu Y, Igaki H.: Commissioning and performance evaluation of commercially available mobile imager for image guided total body irradiation. *J Appl Clin Med Phys.* 24(4): e13865,2023. doi: 10.1002/acm2.13865. (IF: 2.1)
- 58 . Matsumura A, Asano T, Hirose K, Igaki H, Kawabata S, Kumada H.: Initiatives Toward Clinical Boron Neutron Capture Therapy in Japan. *Cancer Biother Radiopharm.* 38(3): 201-207,2023. doi: 10.1089/cbr.2022.0056. (IF: 2.79)
- 59 . Kashihara T, Nakayama Y, Okuma K, Takahashi A, Kaneda T, Katagiri M, Nakayama H, Kubo Y, Ito K, Nakamura S, Takahashi K, Inaba K, Murakami N, Saito T, Okamoto H, Itami J, Kusumoto M, Ohe Y, Igaki H.: Impact of interstitial lung abnormality on survival after adjuvant durvalumab with chemoradiotherapy for locally advanced non-small cell lung cancer. *Radiother Oncol.* 180: 109454,2023. doi: 10.1016/j.radonc.2022.109454. (IF: 4.9)

- 60 . Murakami N, Takano A, Niizeki I, Sakuramachi M, Kashihara T, Okamoto H, Ito M, Ueno T, Igaki H.: Nursing management of patients receiving interstitial brachytherapy for head and neck malignancies. *Brachytherapy*. 22(2): 214-220,2023. doi: 10.1016/j.brachy.2022.10.010. (IF: 1.7)
- 61 . Mizuno N, Okamoto H, Minemura T, Kawamura S, Tohyama N, Kurooka M, Kawamorita R, Nakamura M, Ito Y, Shioyama Y, Aoyama H, Igaki H.: Establishing quality indicators to comprehensively assess quality assurance and patient safety in radiotherapy and their relationship with an institution's background. *Radiother Oncol*. 179: 109452,2023. doi: 10.1016/j.radonc.2022.109452. (IF: 4.9)
- 62 . Murakami N, Okuma K, Takahashi A, Kato T, Igaki H.: Is it time to modify the Japanese Uterine Cervical Cancer Guidelines to recommend a higher dose for radio-resistant tumors?. *Jpn J Clin Oncol*. 53(2): 179-181,2023. doi: 10.1093/jjco/hyac171. (IF: 1.9)
- 63 . Kon M, Okamoto H, Nakamura S, Iijima K, Chiba T, Takemori M, Nakayama H, Nakaichi T, Mikasa S, Fujii K, Urago Y, Ishikawa M, Sofue T, Katsuta S, Inaba K, Igaki H, Aso T.: Planning study: prone versus supine position for stereotactic body radiotherapy in prostate by CyberKnife. *J Radiat Res*. 64(1): 186-194,2023. doi: 10.1093/jrr/rrac065. (IF: 1.94)
- 64 . Murakami N, Sakuramachi M, Kashihara T, Chiba T, Nakamura S, Ono K, Ueno T, Yoshimoto S, Yoshida K, Masui K, Akiyama H, Igaki H.: The combination of volumetric arc radiation therapy and boost high-dose rate interstitial brachytherapy for T3N2c tongue cancer: a technical report. *Jpn J Clin Oncol*. 53(1): 85-90,2023. doi: 10.1093/jjco/hyac160. (IF: 1.9)
- 65 . Takemori M, Nakamura S, Sofue T, Ito M, Goka T, Miura Y, Iijima K, Chiba T, Nakayama H, Nakaichi T, Mikasa S, Takano Y, Kon M, Shuto Y, Urago Y, Nishitani M, Kashihara T, Takahashi K, Murakami N, Nishio T, Okamoto H, Chang W, Igaki H.: Failure modes and effects analysis study for accelerator-based Boron Neutron Capture Therapy. *Med Phys*. 50(1): 424-439,2023. doi: 10.1002/mp.16104. (IF: 3.2)
- 66 . Kashihara T, Ogata D, Okuma K, Nakamura S, Nakayama H, Mori T, Takahashi A, Namikawa K, Takahashi A, Takahashi K, Kaneda T, Inaba K, Murakami N, Okamoto H, Nakayama Y, Yamazaki N, Igaki H.: Clinical significance of local control of primary tumour in definitive radiotherapy for scalp angiosarcomas. *Skin Res Technol*. 29(1): e13243,2023. doi: 10.1111/srt.13243. (IF: 2)
- 67 . Ishiguro A, Ogata D, Okuma K, Kashihara T, Murakami N, Hiki K, Yamakawa K, Jinnai S, Takahashi A, Namikawa K, Igaki H, Yamazaki N.: Malignant melanoma treatment using brachytherapy: Two case reports and 15 case series. *J Dermatol*. 50(1): 94-97,2023. doi: 10.1111/1346-8138.16599. (IF: 3.468)

A-b

- 1 . Ohtsu A, Goto K, Yoshino T: Improvement of patient care using cancer genomic profiling: SCRUM-/CIRCULATE-Japan experience. *Proc Jpn Acad Ser B Phys Biol Sci* 99(8): 241-253,2023. doi: 10.2183/pjab.99.015. (IF: 3.49)

## B 邦文

B-a

- 1 . 田中 悠, 善家 義貴, 後藤 功一, 坪井 正博 : 【外科医によるこれからの癌薬物療法-最新知識と安全で効果的な遂行のコツ-】 肺癌における周術期薬物療法. *日本外科学会雑誌* 124(5): 422-430, 2023.
- 2 . 泉 大樹, 松本 慎吾, 葉 清隆, 小林 進, 後藤 功一 : 【がん遺伝子の発見は現代医療を進歩させたか】 がん遺伝子研究の新しい展開 肺癌の新規ドライバー遺伝子"CLIP1-LTK". *生体の科学* 74(4): 306-311, 2023.
- 3 . 尾見 康夫, 桐田 圭輔, 香川 洋輔, 高橋 真理, 後藤 功一 : AI-assisted benign and malignant classification for Rapid On-Site cytologic Evaluation(ROSE) on lung cancer. *日本医用画像工学会大会予稿集* 42: 159-160, 2023.
- 4 . 笹本 磨央, 酒井 徹也, 大井 肇, 池田 喬哉, 湯田 淳一朗, 後藤 功一 : 免疫性血小板減少性紫斑病をきたした進展型小細胞肺癌の1例. *日本呼吸器学会誌* 12(1): 44-49, 2023.

B-b

- 1 . 後藤 功一, 松本 慎吾, 泉 大樹 : 【肺癌診療の進歩】 進行非小細胞肺癌における個別化医療の確立を目指した遺伝子検査の進歩. *日本内科学会雑誌* 112(6): 945-954, 2023.

## 学会発表数

A-a	A-b		B-a	B-b	
	シンポジウム	学会		シンポジウム	学会
0	1	33	2	9	30

## 社会活動

氏名・職	委員会等名	関係機関名
後藤功一・教授	バイオマーカー委員会	日本肺癌学会
後藤功一・教授	評議員	日本肺癌学会
後藤功一・教授	評議員	日本癌学会
後藤功一・教授	薬事・食品衛生審議会臨時委員	厚生労働省
後藤功一・教授	Associate Editor	Cancer Science
井垣 浩・教授	理事	日本放射線腫瘍学会
井垣 浩・教授	ガイドライン委員長	日本放射線腫瘍学会
井垣 浩・教授	代議員	日本放射線腫瘍学会
井垣 浩・教授	代議員	日本医学放射線学会
井垣 浩・教授	理事長	日本中性子捕捉療法学会
井垣 浩・教授	関西BNCT共同医療センター 運営委員	大阪医科薬科大学
井垣 浩・教授	世話人	日本定位放射線治療学会
井垣 浩・教授	世話人	日本放射線外科学会
井垣 浩・教授	世話人	ニューロ・オンコロジーの会

## 競争的研究資金獲得状況（共同研究を含む）

氏名・職	資金提供元/共同研究先	代表・分担	研究題目
後藤功一・教授	国立研究開発法人日本医療研究開発機構	分担	革新的がん医療実用化研究事業 「肺がん等の全ゲノム配列データおよび臨床情報等の収集と解析に基づく創薬等のイノベーションの創出のための基盤研究」
後藤功一・教授	国立研究開発法人日本医療研究開発機構	分担	革新的がん医療実用化研究事業 「進展型小細胞肺癌に対する新たな治療開発を目指した研究」
後藤功一・教授	国立研究開発法人国立がん研究センター	代表	運営費交付金国立がん研究センター研究開発費 「アジアにおける国際的遺伝子スクリーニング及び個別化治療開発基盤の構築」
井垣 浩・教授	国立研究開発法人日本医療研究開発機構	代表	革新的がん医療実用化研究事業 前立腺癌に対するMR画像誘導即時適応定位放射線治療の臨床応用を目指す研究
井垣 浩・教授	国立研究開発法人日本医療研究開発機構	分担	革新的がん医療実用化研究事業 可及的摘出術が行われた初発膠芽腫に対するカルムスチン脳内留置用剤を用いた標準治療確立に関する研究
井垣 浩・教授	厚生労働省	分担	がん対策推進総合研究事業 放射線療法の提供体制構築に資する研究
井垣 浩・教授	日本学術振興会	分担	国際共同研究加速基金(国際共同研究強化(B)) 国際標準計測機器による各国のBNCT装置の中性子ビームの測定と国際比較評価
井垣 浩・教授	国立研究開発法人日本医療研究開発機構	代表	医薬品等規制調和・評価研究事業 ホウ素中性子捕捉療法用中性子照射装置の中性子ビーム特性評価の標準化に関する研究開発
井垣 浩・教授	国立研究開発法人日本医療研究開発機構	分担	革新的がん医療実用化研究事業 高齢者初発膠芽腫に対するテモゾロミド併用寡分割放射線治療の最適化に関する研究

井垣 浩・教授	国立研究開発法人日本医療研究開発機構	分担	革新的がん医療実用化研究事業 造影病変全切除可能な初発膠芽腫に対する標準的手術法確立に関する研究
井垣 浩・教授	国立研究開発法人日本医療研究開発機構	分担	革新的がん医療実用化研究事業 難治性悪性脳腫瘍の中性子捕捉療法薬剤の開発
井垣 浩・教授	日本学術振興会	分担	基盤研究(B)(一般) 多発転移性腎癌におけるニボルマブと放射線治療の相乗効果を検証する無作為比較試験
後藤功一・教授	バイエル薬品株式会社		LC-SCRUM-Support：臨床試験情報の患者提供システムを活用し、治験への登録を推進し、個別化医療の確立を目指す研究
後藤功一・教授	株式会社理研ジェネシス		細胞診検体を用いたマルチ遺伝子診断法の確立と臨床応用を目指した研究
後藤功一・教授	中外製薬株式会社		早期非小細胞肺癌における周術期個別化医療の確立を目指した、遺伝子スクリーニングとモニタリングのための多施設共同前向き観察研究 (LC-SCRUM-Advantage/MRD)
後藤功一・教授	大鵬薬品工業株式会社		LC-SCRUM-Support：臨床試験情報の患者提供システムを活用し、治験への登録を推進し、個別化医療の確立を目指す研究
後藤功一・教授	大鵬薬品工業株式会社		非小細胞肺癌における薬物治療耐性後の個別化医療の確立を目指した、遺伝子スクリーニングとモニタリングのための多施設共同前向き観察研究：LC-SCRUM-TRY
後藤功一・教授	Lunit Inc.		【Annexure A】 The prospective observational study of evaluation of PD-L1 Immunostaining by Histopathological Image Analysis Using Artificial Intelligence (AI) in LC-SCRUM-Advantage
後藤功一・教授	Lunit Inc.		【Annexure B】 The retrospective study of evaluation of PD-L1 Immunostaining by Histopathological Image Analysis Using Artificial Intelligence (AI) in LC-SCRUM-IBIS
後藤功一・教授	GUARDANT HEALTH AMEA, INC.		Lung Cancer Genomic Screening Project for Neoadjuvant and Adjuvant setting Molecular Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer and the Assessment of monitoring Minimal Residual Disease (LC-SCRUM-Advantage/MRD)
後藤功一・教授	小野薬品工業(株)、日本ベーリンガーインゲルハイム(株)、中外製薬(株)、武田薬品工業(株)、(株)医学生物学研究所、大鵬薬品工業(株)、第一三共(株)、エーザイ(株)、協和キリン(株)、大日本住友ファーマ(株)、Amgen Inc、MSD(株)、日本イーライリリー(株)、バイエル薬品(株)、Merus、ファイザー(株)ノバルティスファーマ(株)、アストラゼネカ(株)、アッヴィ合同会社、ブリistolマイヤーズスクイブ(株)		SCRUM-Japanに基づく遺伝子変異スクリーニングに関する共同研究(4期)
井垣 浩・教授	株式会社CICS/ ステラファーマ株式会社		切除不能な血管肉腫を対象としたCICS-1とSPM-011を用いたホウ素中性子捕捉療法(BNCT)の第II相臨床試験
井垣 浩・教授	エレクトラ株式会社		前立腺癌に対する高線量率組織内照射単独療法の多施設共同臨床試験

井垣 浩・教授	エレクタ株式会社	Patient Monitoring application “Kaiku” を用いた予後フォローアップおよびその有用性
井垣 浩・教授	ステラファーマ株式会社/株式会社CICS/住友重機械工業株式会社	標準治療困難かつ切除不能な再発の胸部固形悪性腫瘍患者に対するCICS-1とSPM-011 のホウ素中性子捕捉療法 (BNCT) の第I/II相バスケット試験

## その他

### 非常勤講師

氏名・職	職 (担当科目)	関係機関名
井垣 浩・教授	非常勤講師 (中性子医療コース)	岡山大学大学院

### 新聞等に掲載された活動

氏名・職	活動題目	掲載紙誌等	掲載年月日	活動内容の概要と社会との関連
後藤功一・教授	執筆	読売新聞 (土曜夕刊医療面)	2023年4月1日	一般読者に向けがんの医療現場の現状などを分かりやすく提供

### 学術賞受賞

氏名・職	賞の名称	授与機関名	授賞理由、研究内容等
小野拓也 大学院生	ポスター賞	日本患者由来がんモデル学会	隆起性皮膚線維肉腫の薬剤探索に向けた患者由来細胞株の樹立と応用
小野拓也 大学院生	一般演題優秀賞	第74回日本電気泳動学会学術大会	線維肉腫様の隆起性皮膚線維肉腫の治療法開発に向けての患者由来細胞株を用いた研究
小野拓也 大学院生	Presentation Award	Human Proteome Organization	Proteomic analysis to identify the molecular differences between dermatofibrosarcoma protuberans and fibrosarcomatous dermatofibrosarcoma protuberans
小野拓也 大学院生	長崎大学令和4年度長崎大学学長賞	長崎大学	がん微小環境再現に向けた新規培養系の構築

### 特筆すべき事項

希少がん研究分野では、希少がんの臨床に役立つ成果を目指した基礎研究が行われています。我々の研究があってよかったと、いつの日か患者さん、医療従事者の方、そして世界中の方々に思ってもらえるような研究成果を目指しています。

中野愛里. 長崎大学卓越大学院プログラム、Analysis of the role of p53-PAD7-YAP/TAZ pathway in deciding cell fate and oncogenesis of hepatocarcinoma. 2023年10月採択

中野愛里. 公益財団法人双葉電子記念財団奨学会の給付型奨学金に2023年9月に採択されたが、上の長崎大学卓越大学院の給付金との併用不可のため辞退。